This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tremblay, C. L. Articles by Hirsch, M. S. Search for Related Content PubMed PubMed Citation Articles by Tremblay, C. L. Articles by Hirsch, M. S.

TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro

Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Cambridge, Massachusetts,¹ Memorial Sloan-Kettering Cancer Center, New York, New York,² Takeda Pharmaceutical Company, Ltd., Osaka, Japan,³ Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada⁴

Received 22 December 2004/ Returned for modification 8 March 2005/ Accepted 25 April 2005

TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.

This article has been cited by other articles:

• Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., Olson, W. C. (2006). Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1.. Antimicrob. Agents Chemother. 50: 3289-3296 [Abstract] [Full Text]